Table 2 |
||||
| Prescribed medication at baseline and at 6-months follow-up for those who remained in the trial (n = 146) | ||||
| Drug class | Baseline data for those who remained in the trial | Data at 6-months follow-up | ||
| Intervention n = 59 | Control n = 60 | Intervention n = 59 | Control n = 60 | |
| Antithrombotica | ||||
| Acetylsalicylic acid (aspirin) | 47 (79.7%) | 54 (90.0%) | 49 (83.1%) | 52 (86.7%) |
| Blood pressure-lowering medication | ||||
| Angiotensin-converting enzyme (ACE inhibitors) | 24 (40.7%) | 21 (35.0%) | 27 (45.8%) | 20 (33.3%) |
| β-blocker | 34 (57.6%) | 38 (63.3%) | 33 (55.9%) | 40 (66.7%) |
| Calcium-channel blocker | 12 (20.3%) | 19 (31.7%) | 16 (27.1%) | 18 (30.0%) |
| Diuretica | 12 (20.3%) | 12 (20.0%) | 12 (20.3%) | 10 (16.7%) |
| Lipid-lowering medication | ||||
| Statins | 51 (86.4%) | 49 (81.7%) | 53 (89.8%) | 54 (90.0%) |
| Blood glucose-lowering medicationa | ||||
| Biguanides | 9 (15.3%) | 7 (11.7%) | 10 (16.9%) | 7 (11.7%) |
n=number of patients; %, percentage of patients who remained in the study; adata based on diabetic patients at baseline and at 6-months follow-up.
IJzelenberg et al. BMC Cardiovascular Disorders 2012 12:71 doi:10.1186/1471-2261-12-71
